1. Home
  2. CRVO
  3. CRVO News

Latest CervoMed Inc. (CRVO) News on January 19, 2025

CervoMed price target lowered to $4 from $45 at Roth MKM
CRVO

TipRanks

a month ago

CervoMed price target lowered to $4 from $45 at Roth MKM

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRVO

GlobeNewswire

a month ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRVO

MT Newswires

a month ago

Morgan Stanley Downgrades CervoMed to Underweight From Overweight

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CRVO

TipRanks

a month ago

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CRVO

MT Newswires

a month ago

Chardan Downgrades CervoMed to Neutral From Buy, Withdraws $55 Price Target

CRVO

MT Newswires

a month ago

Top Midday Decliners

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CRVO

Benzinga

a month ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CRVO

MT Newswires

a month ago

Brookline Downgrades CervoMed to Hold From Buy; Shares Plunge

CRVO

MT Newswires

a month ago

CervoMed Shares Plunge After Dementia Treatment Fails to Meet Trial Endpoints

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
CRVO

GlobeNewswire

a month ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CRVO

MT Newswires

a month ago

Roth Initiates CervoMed at Buy With $45 Price Target

CRVO

MT Newswires

a month ago

HC Wainwright Initiates CervoMed at Buy With $42 Price Target

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug
CRVO

Pharmaceutical Technology

2 months ago

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

CRVO

MT Newswires

2 months ago

CervoMed Says it Gets FDA's Orphan Drug Designation for Neflamapimod to Treat Frontotemporal Dementia

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CRVO

GlobeNewswire

2 months ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Announces Key Senior Leadership Appointments
CRVO

GlobeNewswire

2 months ago

CervoMed Announces Key Senior Leadership Appointments

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

2 months ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CRVO

GlobeNewswire

2 months ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

2 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CRVO

GlobeNewswire

2 months ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
CRVO

GlobeNewswire

3 months ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
CRVO

GlobeNewswire

3 months ago

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

CervoMed Ends $20 Million Stock Sales Agreement with BTIG
CRVO

TipRanks

3 months ago

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

CRVO

MT Newswires

4 months ago

CervoMed Files $250 Million Mixed Shelf

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
CRVO

GlobeNewswire

4 months ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CRVO

GlobeNewswire

4 months ago

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently
CRVO

Simply Wall St.

4 months ago

With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CRVO

Zacks

4 months ago

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?

CRVO

MT Newswires

4 months ago

Chardan Initiates CervoMed at Buy With $55 Price Target

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

5 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
CRVO

GlobeNewswire

5 months ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

5 months ago

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Second Quarter 2024 Earnings: Beats Expectations
CRVO

Simply Wall St.

5 months ago

CervoMed Second Quarter 2024 Earnings: Beats Expectations

Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks
CRVO

TipRanks

5 months ago

Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
CRVO

GlobeNewswire

6 months ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CRVO

MT Newswires

6 months ago

CervoMed Reports Plasma Biomarker Data Show Neflamapimod Lowers GFAP Levels

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
CRVO

GlobeNewswire

6 months ago

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

CervoMed to Participate in the Emerging Growth Conference
CRVO

GlobeNewswire

6 months ago

CervoMed to Participate in the Emerging Growth Conference

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
CRVO

GlobeNewswire

6 months ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
CRVO

GlobeNewswire

6 months ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans
CRVO

Simply Wall St.

7 months ago

CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
CRVO

GlobeNewswire

7 months ago

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CRVO

GlobeNewswire

7 months ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…
CRVO

Zacks Small Cap Research

8 months ago

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…

CRVO

MT Newswires

8 months ago

--JonesTrading Starts CervoMed With Buy Rating, $70 Price Target

CRVO

MT Newswires

8 months ago

CervoMed Names William Elder CFO

CervoMed to Appoint William Elder as Chief Financial Officer
CRVO

GlobeNewswire

8 months ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

8 months ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…
CRVO

Zacks Small Cap Research

9 months ago

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CRVO

GlobeNewswire

10 months ago

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

10 months ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

10 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
CRVO

GlobeNewswire

10 months ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Inc.'s (NASDAQ:CRVO): Top Key Executive Sylvie Gregoire is the most bullish insider, and their stock value gained 29% last week
CRVO

Simply Wall St.

10 months ago

CervoMed Inc.'s (NASDAQ:CRVO): Top Key Executive Sylvie Gregoire is the most bullish insider, and their stock value gained 29% last week

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
CRVO

GlobeNewswire

10 months ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
CRVO

News Direct

a year ago

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
CRVO

GlobeNewswire

a year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
CRVO

GlobeNewswire

a year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
CRVO

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now

CervoMed to Participate in the Emerging Growth Conference 67
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in the Emerging Growth Conference 67

Charter Communications (CHTR) Lags Q4 Earnings and Revenue Estimates
CRVO

Zacks

a year ago

Charter Communications (CHTR) Lags Q4 Earnings and Revenue Estimates

LiveOne's (Nasdaq: LVO) Slacker Radio Partners With Legible Inc. Giving Access to Millions of Audiobooks and Ebooks for Its Members, Including Audiobook Previews for 1.5M+ Tesla Drivers
CRVO

NewMediaWire

a year ago

LiveOne's (Nasdaq: LVO) Slacker Radio Partners With Legible Inc. Giving Access to Millions of Audiobooks and Ebooks for Its Members, Including Audiobook Previews for 1.5M+ Tesla Drivers

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks
CRVO

StockStory

a year ago

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
CRVO

Zacks

a year ago

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

Chuck Royce Trims Position in Manitex International Inc
CRVO

GuruFocus.com

a year ago

Chuck Royce Trims Position in Manitex International Inc

We're Not Very Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Rate
CRVO

Simply Wall St.

a year ago

We're Not Very Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Rate

Bright Health Group Adopts NeueHealth as Corporate Brand Name
CRVO

Business Wire

a year ago

Bright Health Group Adopts NeueHealth as Corporate Brand Name

Can Flexsteel (FLXS) Run Higher on Rising Earnings Estimates?
CRVO

Zacks

a year ago

Can Flexsteel (FLXS) Run Higher on Rising Earnings Estimates?

Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
CRVO

Zacks

a year ago

Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why

Is Flexsteel Industries (FLXS) Stock Outpacing Its Consumer Discretionary Peers This Year?
CRVO

Zacks

a year ago

Is Flexsteel Industries (FLXS) Stock Outpacing Its Consumer Discretionary Peers This Year?

LifeVantage to Announce Second Quarter Fiscal Year 2024 Results on January 30, 2024
CRVO

GlobeNewswire

a year ago

LifeVantage to Announce Second Quarter Fiscal Year 2024 Results on January 30, 2024

LifeVantage Hosts Global Kickoff Announcing “Rise ERA” Theme, New Sales Incentives and Global Expansion Dates for LV360
CRVO

GlobeNewswire

a year ago

LifeVantage Hosts Global Kickoff Announcing “Rise ERA” Theme, New Sales Incentives and Global Expansion Dates for LV360

U.S. GoldMining Intersects 547 meters at 1.06 g/t Gold Equivalent Including 176 meters at 1.55 g/t Gold Equivalent at the Whistler Gold-Copper Project, Alaska
CRVO

CNW Group

a year ago

U.S. GoldMining Intersects 547 meters at 1.06 g/t Gold Equivalent Including 176 meters at 1.55 g/t Gold Equivalent at the Whistler Gold-Copper Project, Alaska

Platinum Group Metals Ltd. Reports First Quarter Results
CRVO

Newsfile

a year ago

Platinum Group Metals Ltd. Reports First Quarter Results

Ondas Holdings' Airobotics Secures Purchase Order from One of the World’s Largest Semiconductor Manufacturers for Drone Aerial Security and Data Services at Fabrication Facility in Israel
CRVO

ACCESSWIRE

a year ago

Ondas Holdings' Airobotics Secures Purchase Order from One of the World’s Largest Semiconductor Manufacturers for Drone Aerial Security and Data Services at Fabrication Facility in Israel

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream
CRVO

GlobeNewswire

a year ago

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream

CRVO

Business Wire

a year ago

Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices – Dream Sock® and BabySat™

Semantix Provides Update Regarding Nasdaq Minimum Bid Price Compliance
CRVO

GlobeNewswire

a year ago

Semantix Provides Update Regarding Nasdaq Minimum Bid Price Compliance

CervoMed to Participate in the Emerging Growth Conference 66
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in the Emerging Growth Conference 66

Investors in Heritage Global (NASDAQ:HGBL) have seen fantastic returns of 480% over the past five years
CRVO

Simply Wall St.

a year ago

Investors in Heritage Global (NASDAQ:HGBL) have seen fantastic returns of 480% over the past five years

Invesco Closed-End Funds Pay Dividends
CRVO

PR Newswire

a year ago

Invesco Closed-End Funds Pay Dividends

Abercrombie (ANF) Up 23.5% Since Last Earnings Report: Can It Continue?
CRVO

Zacks

a year ago

Abercrombie (ANF) Up 23.5% Since Last Earnings Report: Can It Continue?

12 Best Lithium and Battery Stocks to Buy According to Financial Media
CRVO

Insider Monkey

a year ago

12 Best Lithium and Battery Stocks to Buy According to Financial Media

Here's What's Concerning About LifeVantage's (NASDAQ:LFVN) Returns On Capital
CRVO

Simply Wall St.

a year ago

Here's What's Concerning About LifeVantage's (NASDAQ:LFVN) Returns On Capital

Arrowmark Financial Corp. Announces Q3 2023 Results and Releases Month End Estimated Net Asset Value as of November 2023
CRVO

GlobeNewswire

a year ago

Arrowmark Financial Corp. Announces Q3 2023 Results and Releases Month End Estimated Net Asset Value as of November 2023

7 Promising Penny Stocks With the Potential to Defy Expectations
CRVO

InvestorPlace

a year ago

7 Promising Penny Stocks With the Potential to Defy Expectations

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
CRVO

GlobeNewswire

a year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) top owners are individual investors with 55% stake, while 45% is held by insiders
CRVO

Simply Wall St.

a year ago

Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) top owners are individual investors with 55% stake, while 45% is held by insiders

Kewaunee Scientific Corporation's (NASDAQ:KEQU) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
CRVO

Simply Wall St.

a year ago

Kewaunee Scientific Corporation's (NASDAQ:KEQU) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Syntec Optics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference (Nasdaq: OPTX)
CRVO

GlobeNewswire

a year ago

Syntec Optics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference (Nasdaq: OPTX)

CRVO

PR Newswire

a year ago

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

With 63% ownership, Timberland Bancorp, Inc. (NASDAQ:TSBK) boasts of strong institutional backing
CRVO

Simply Wall St.

a year ago

With 63% ownership, Timberland Bancorp, Inc. (NASDAQ:TSBK) boasts of strong institutional backing

CRVO

CNW Group

a year ago

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

Sangoma to Showcase Innovations at Benchmark Discovery One-on-One Conference in New York
CRVO

Business Wire

a year ago

Sangoma to Showcase Innovations at Benchmark Discovery One-on-One Conference in New York

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock
CRVO

Zacks

a year ago

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock

Endeavour Silver Hosts Investor Day and Analyst Site Visit
CRVO

GlobeNewswire

a year ago

Endeavour Silver Hosts Investor Day and Analyst Site Visit

12 Best Recycling Stocks To Buy Now
CRVO

Insider Monkey

a year ago

12 Best Recycling Stocks To Buy Now

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
CRVO

GlobeNewswire

a year ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate
CRVO

Simply Wall St.

a year ago

We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate

Share on Social Networks: